Toronto Dominion Bank Makes New $24.88 Million Investment in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Toronto Dominion Bank acquired a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 540,024 shares of the company's stock, valued at approximately $24,879,000. Toronto Dominion Bank owned 1.93% of Establishment Labs at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Quarry LP acquired a new position in Establishment Labs during the fourth quarter valued at $27,000. R Squared Ltd purchased a new position in shares of Establishment Labs during the 4th quarter valued at about $36,000. KLP Kapitalforvaltning AS acquired a new position in shares of Establishment Labs in the 4th quarter valued at about $161,000. Hood River Capital Management LLC lifted its holdings in shares of Establishment Labs by 236.4% in the 4th quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock valued at $273,000 after buying an additional 4,160 shares during the period. Finally, Handelsbanken Fonder AB boosted its stake in shares of Establishment Labs by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after buying an additional 2,000 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded down $1.21 during midday trading on Thursday, reaching $34.68. 461,601 shares of the company's stock traded hands, compared to its average volume of 474,163. The company has a fifty day simple moving average of $34.01 and a two-hundred day simple moving average of $37.64. Establishment Labs Holdings Inc. has a 1 year low of $26.56 and a 1 year high of $58.00. The company has a market cap of $1.00 billion, a P/E ratio of -13.44 and a beta of 0.73. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $41.38 million for the quarter, compared to the consensus estimate of $41.15 million. During the same period last year, the firm posted ($0.58) earnings per share. The company's revenue was up 11.3% compared to the same quarter last year. Equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ESTA shares. Stephens reiterated an "overweight" rating and set a $52.00 price target on shares of Establishment Labs in a research report on Thursday, March 6th. Needham & Company LLC raised shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 target price for the company in a report on Wednesday, May 14th. BTIG Research initiated coverage on shares of Establishment Labs in a research note on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Finally, Wall Street Zen lowered shares of Establishment Labs from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $55.33.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.